Imaging the functional biomarker of photoreceptors

光感受器功能生物标志物成像

• 批准号: 9239662
• 负责人: Shuliang Jiao
• 金额: $ 49.52万
• 依托单位: FLORIDA INTERNATIONAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9239662
• 关键词: Age; Age related macular degeneration; Algorithms; American; Anatomy; Animal Model; Biological Markers; Blindness; Cells; Clinic; Clinical; Clinical Trials; Computer software; Darkness; Data Set; Degenerative Disorder; Developed Countries; Developing Countries; Development; Diagnosis; Disadvantaged; Disease; Disease Progression; Elderly; Electroretinography; Evaluation; Extinction (Psychology); Feedback; Functional Imaging; Future; Genotype; Health Care Costs; Image; Imaging Device; Imaging technology; Impairment; Inherited; Light; Maps; Measurement; Measures; Modality; Modeling; Monitor; Mus; Normal Range; Ophthalmology; Optical Coherence Tomography; Patient Care; Patients; Phase; Photoreceptors; Population; Procedures; Rattus; Retina; Retinal; Retinal Cone; Retinal Degeneration; Retinitis Pigmentosa; Rhodopsin; Scanning; Signal Transduction; Societies; Solid; Staging; Staining method; Stains; Standardization; Stargardt' s disease; Structure; System; Techniques; Technology; Testing; Theoretical model; Time; Transgenic Organisms; United States; Visible Radiation; Vision; Visual; Visual Acuity; Visual Fields; absorption; anatomic imaging; base; clinical application; density; design; disability; experimental study; follow-up; human subject; imaging system; improved; in vivo; in vivo imaging; neurotransmission; novel; photoreceptor degeneration; quantitative imaging; response; retinal rods; tool

Project Summary-Abstract “Vision is the most fundamental of our senses and it is perhaps the greatest tragedy of all when blindness robs us of this modality”. Photoreceptors are light-detecting cells initiating vision. Loss of photoreceptor leads to loss of vision. This happens in millions of Americans with hereditary retinal degenerations or age-related macular degeneration (AMD). Loss of vision is not only a personal tragedy but also a burden to the society. It is estimated that a patient with retinitis pigmentosa (RP) has an average health care cost of $7,000/year, more than that of age-matched non-RP patients. We want to develop three new in vivo imaging technologies for mapping rhodopsin, the functional and anatomic biomarker of rod photoreceptors. Based on our in-depth analysis of the clinical needs of today and in the near future for monitoring the function and anatomy of photoreceptors, we believe it will be a game changer for the diagnosis, monitoring, and treatment evaluation for retinal degenerative disorders, including hereditary retinal degeneration, AMD, and other diseases. This application has the following hypotheses: 1, Visible-light OCT (VIS-OCT) provide depth resolved information for segmentation to measure the levels and distribution of rhodopsin accurately; 2, The amount of rhodopsin can be calculated from measurements of absorbance at different wavelengths located in the rhodopsin absorption spectrum; 3, Imaging devices based on the VIS-OCT technologies could provide information to assess the levels and distribution of rhodopsin in patients. This proposal has three Specific Aims. In Aim 1, We will develop and refine three VIS-OCT based imaging technologies: a Single-Band VIS-OCT with a center wavelength of 520 nm close to the peak absorption of rhodopsin; a Tri-Band VIS-OCT that uses three bands of probing light spanning the rhodopsin absorption spectrum; and a Broad-Band VIS-OCT that uses a continuous spectrum covering the rhodopsin absorption wavelengths from 520 nm to 580 nm. The Single-Band technology will image the retina twice, once dark-adapted and then light adapted. With the Tri-Band and Broad-Band VIS- OCTs rhodopsin content will be calculated from the simultaneously acquired OCT images based on the different molar extinction coefficients of rhodopsin at different wavelengths. Since the Tri-Band and Broad- Band technologies only need to image the retina once in the dark-adapted state, it would be much more clinical friendly. In Aim 2, we will use animal models to test and fine-tune the three VIS-OCTs. In Aim 3, we will test the three OCT systems in human subjects to provide vital feedback to improve and fine-tune the hardware and software, and to establish rhodopsin ranges of normal retina and retinas of different stages of diseases. We expect to have the three systems clinically ready by the end of this project. Successful completion of the proposed experiments would add a powerful technology to ophthalmology clinics for care of patient with retinal degenerative diseases.

项目摘要提取 “视觉是我们感官中最基本的，当盲人抢劫时，这可能是所有人中最大的悲剧 这种方式的我们”。感光体是启动视觉的光检测细胞。失去感受器会导致损失 视觉。这发生在数百万的美国人具有遗传性视网膜变性或与年龄有关的黄斑 变性（AMD）。视力丧失不仅是个人悲剧，而且是对社会的负担。这是 据估计，色素性视网膜炎（RP）的患者的平均医疗保健费用为每年7,000美元，更多 比年龄匹配的非RP患者的患者。我们想开发三种新的体内成像技术 映射视紫红质，Rod感光体的功能性和解剖生物标志物。基于我们的深入 分析当今和不久的将来的临床需求，以监视功能和解剖 感光器，我们认为它将改变诊断，监测和治疗评估的游戏规则改变者 对于永久性退化性疾病，包括养生的永久性退化，AMD和其他疾病。这 应用具有以下假设：1，可见光OCT（VIS-OCT）提供深度解决信息 为了进行分割，可以准确测量视紫红质的水平和分布； 2，视紫红质的量 可以根据位于Rhopopsin的不同波长的吸光度测量来计算 抽象光谱； 3，基于Vis-OCT技术的成像设备可以向 评估患者视紫红质的水平和分布。该提案具有三个具体目标。在AIM 1中，我们 将开发和完善三种基于VIS-OCT的成像技术：一个带有中心的单波段 520 nm的波长接近视紫红质的峰值滥用；使用三个频段的三个波段 探测跨越视紫红质滥用光谱的光；以及使用连续的宽带 覆盖520 nm至580 nm的视紫红质滥用波长的光谱。单频技术 将两次映像视网膜，一旦变成黑暗，然后改编了光。带有三频和宽带的粘性 OCTS Rhodopsin含量将根据基于简单获得的OCT图像计算 不同波长的视紫红质的不同摩尔延伸系数。由于三频和广泛 频段技术只需要在黑暗适应状态下对视网膜进行成像，它将更加临床 友好的。在AIM 2中，我们将使用动物模型来测试和调整这三个Vis-Octs。在AIM 3中，我们将测试 人类受试者中的三个OCT系统提供重要反馈，以改善和调整硬件和 软件，并建立正常视网膜和视网膜不同阶段疾病的视紫红质范围。我们 期望在该项目结束时准备三个系统在临床上准备好。成功完成 拟议的实验将为眼科诊所增加一项强大的技术，以照顾残留的患者 退化性疾病。